Sentiment-Signal
26,3
Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Unternehmen & Branche
| Name | ABEONA THERAPEUTICS INC. |
|---|---|
| Ticker | ABEO |
| CIK | 0000318306 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 307,2 Mio. USD |
| Beta | 1,21 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 5,820,000 | 71,183,000 | 1.01 | 219,570,000 | 159,216,000 |
| 2025-09-30 | 10-Q | 400,000 | -5,161,000 | -0.10 | 231,095,000 | 171,233,000 |
| 2025-06-30 | 10-Q | 400,000 | 108,833,000 | 1.71 | 246,233,000 | 163,576,000 |
| 2025-03-31 | 10-Q | -12,029,000 | -0.24 | 99,364,000 | 41,396,000 | |
| 2024-12-31 | 10-K | -63,734,000 | -1.55 | 108,931,000 | 44,031,000 | |
| 2024-09-30 | 10-Q | -30,269,000 | -0.63 | 120,592,000 | 45,773,000 | |
| 2024-06-30 | 10-Q | 7,406,000 | -0.26 | 134,003,000 | 73,241,000 | |
| 2024-03-31 | 10-Q | -31,578,000 | -1.16 | 74,828,000 | -8,881,000 | |
| 2023-12-31 | 10-K | 3,500,000 | -54,188,000 | -2.53 | 64,002,000 | 14,826,000 |
| 2023-09-30 | 10-Q | 3,500,000 | -11,836,000 | -0.48 | 66,087,000 | 22,038,000 |
| 2023-06-30 | 10-Q | 3,500,000 | -16,654,000 | -0.92 | 53,550,000 | 9,345,000 |
| 2023-03-31 | 10-Q | -9,107,000 | -0.54 | 53,345,000 | 18,740,000 | |
| 2022-12-31 | 10-K | 1,414,000 | -39,696,000 | -5.53 | 64,214,000 | 26,761,000 |
| 2022-09-30 | 10-Q | 1,346,000 | -6,434,000 | -1.00 | 38,761,000 | 12,401,000 |
| 2022-06-30 | 10-Q | 1,000,000 | -4,097,000 | 1.36 | 44,719,000 | 14,024,000 |
| 2022-03-31 | 10-Q | 346,000 | -22,044,000 | 55,172,000 | 21,183,000 | |
| 2021-12-31 | 10-K | 3,000,000 | -84,936,000 | 79,586,000 | 42,368,000 | |
| 2021-09-30 | 10-Q | -7,044,000 | 119,019,000 | 79,744,000 | ||
| 2021-06-30 | 10-Q | -15,207,000 | 130,675,000 | 84,086,000 | ||
| 2021-03-31 | 10-Q | -16,002,000 | 141,432,000 | 94,390,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Seshadri Vishwas | Director, Officer, Chief Executive Officer | Open Market Sale | -29,985 | 4.38 | -131,481.23 | -136,5% | |
| 2026-03-16 | Vazzano Joseph Walter | Officer, Chief Financial Officer | Open Market Sale | -785 | 4.76 | -3,736.60 | -3,9% | |
| 2026-02-02 | Alvino Mark | Director | Open Market Sale | -2,000 | 5.09 | -10,181.20 | -10,6% | |
| 2026-02-02 | Crombez Eric | Director | Open Market Sale | -16,284 | 5.09 | -82,895.33 | -86,1% | |
| 2026-02-02 | Wuchterl Donald A. | Director | Open Market Sale | -14,814 | 5.09 | -75,412.15 | -78,3% | |
| 2026-02-02 | Silverstein Christine Berni | Director | Open Market Sale | -20,070 | 5.09 | -102,168.34 | -106,1% | |
| 2026-02-02 | Alland Leila | Director | Open Market Sale | -18,065 | 5.09 | -91,961.69 | -95,5% | |
| 2026-01-22 | O'Malley Brendan M. | Officer, SVP, Chief Legal Officer | Open Market Sale | -13,578 | 5.33 | -72,382.96 | -75,2% | |
| 2026-01-22 | Vasanthavada Madhav | Officer, Chief Commercial Officer | Open Market Sale | -12,610 | 5.29 | -66,657.72 | -69,2% | |
| 2026-01-22 | Vazzano Joseph Walter | Officer, Chief Financial Officer | Open Market Sale | -18,666 | 5.33 | -99,506.58 | -103,3% | |
| 2026-01-22 | Seshadri Vishwas | Director, Officer, Chief Executive Officer | Open Market Sale | -69,832 | 5.33 | -372,267.41 | -386,5% | |
| 2026-01-21 | Alvino Mark | Director | Open Market Sale | -13,500 | 5.23 | -70,573.95 | -73,3% | |
| 2025-12-29 | Seshadri Vishwas | Director, Officer, Chief Executive Officer | Open Market Sale | -25,000 | 5.31 | -132,740.00 | -137,8% | |
| 2025-11-13 | Alvino Mark | Director | Open Market Sale | -15,000 | 4.74 | -71,167.50 | -73,9% | |
| 2025-10-16 | Seshadri Vishwas | Director, Officer, Chief Executive Officer | Open Market Sale | -249 | 5.49 | -1,365.77 | -1,4% | |
| 2025-09-30 | Seshadri Vishwas | Director, Officer, Chief Executive Officer | Open Market Sale | -25,000 | 5.24 | -130,930.00 | -135,9% | |
| 2025-09-29 | Vazzano Joseph Walter | Officer, Chief Financial Officer | Open Market Sale | -9,035 | 5.39 | -48,730.27 | -50,6% | |
| 2025-09-29 | Seshadri Vishwas | Director, Officer, Chief Executive Officer | Open Market Sale | -19,274 | 5.39 | -103,954.32 | -107,9% | |
| 2025-09-29 | O'Malley Brendan M. | Officer, SVP, Chief Legal Officer | Open Market Sale | -9,366 | 5.39 | -50,515.52 | -52,4% | |
| 2025-09-22 | O'Malley Brendan M. | Officer, SVP, Chief Legal Officer | Open Market Sale | -688 | 5.43 | -3,735.84 | -3,9% | |
| 2025-08-15 | Vazzano Joseph Walter | Officer, Chief Financial Officer | Open Market Sale | -15,000 | 7.36 | -110,358.00 | -114,6% | |
| 2025-08-14 | Crombez Eric | Director | Open Market Sale | -4,718 | 6.93 | -32,683.00 | -33,9% | |
| 2025-07-22 | Vazzano Joseph Walter | Officer, Chief Financial Officer | Open Market Sale | -1,502 | 6.64 | -9,974.63 | -10,4% | |
| 2025-07-09 | Silverstein Christine Berni | Director | Open Market Sale | -13,093 | 5.86 | -76,668.68 | -79,6% | |
| 2025-07-09 | Alvino Mark | Director | Open Market Sale | -13,093 | 5.86 | -76,668.68 | -79,6% | |
| 2025-07-09 | Vazzano Joseph Walter | Officer, Chief Financial Officer | Open Market Sale | -25,411 | 5.86 | -148,799.19 | -154,5% | |
| 2025-07-09 | O'Malley Brendan M. | Officer, SVP, Chief Legal Officer | Open Market Sale | -17,428 | 5.86 | -102,053.14 | -106,0% | |
| 2025-07-09 | Seshadri Vishwas | Director, Officer, Chief Executive Officer | Open Market Sale | -69,420 | 5.86 | -406,502.69 | -422,1% | |
| 2025-07-09 | Charles Faith L. | Director | Open Market Sale | -10,738 | 5.86 | -62,878.51 | -65,3% | |
| 2025-07-08 | Wuchterl Donald A. | Director | Open Market Sale | -5,176 | 5.82 | -30,147.09 | -31,3% | |
| 2025-06-06 | Vazzano Joseph Walter | Officer, Chief Financial Officer | Open Market Sale | -17,795 | 6.76 | -120,294.20 | -124,9% | |
| 2025-06-06 | O'Malley Brendan M. | Officer, SVP, General Counsel | Open Market Sale | -10,470 | 6.76 | -70,777.20 | -73,5% | |
| 2025-06-06 | Seshadri Vishwas | Director, Officer, Chief Executive Officer | Open Market Sale | -50,676 | 6.76 | -342,569.76 | -355,7% | |
| 2025-05-27 | Alvino Mark | Director | Open Market Sale | -2,000 | 6.38 | -12,760.00 | -13,2% | |
| 2025-05-16 | Alvino Mark | Director | Open Market Sale | -8,000 | 5.68 | -45,440.00 | -47,2% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.